LUMO - Earnings call transcript Q2 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to Lumos Pharma's Second Quarter Results Conference Call. Currently, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time.

As a reminder, this conference call is being recorded. I will now turn the call over to Lisa Miller, Senior Director of Investor Relations. ahead. go please am Ma'

Lisa Miller

Thank you.

Federal we the differ and to are uncertainties I statements materially U.S. like that could results historical with everyone Before forward-looking subject that to risks under call from call, expectations. remind this certain would during experience These present actual proceed statements to laws. Securities cause statements are made or

The that is filed be undertakes hereof, concerning on factors of from could page relations statements SEC. contained the or this update with earnings the revise our company's information results as presented contained of differ cause this Additional website. to and during is reports in statements. periodic may the only in the call Information this forward-looking no made actual accessed obligation call issued the speak release company investor these to we date the forward-looking which afternoon,

John Joining Corporate me and Lawley, call Hawkins, Officer; are Financial Chief and Rick on and today's David and Karpf, Officer Officer, Chief McKew, Chief Scientific Lori Medical President Controller. Dr. B. Chairman; CEO

Rick. management we will open to I will the Following now turn prepared call over to your the call remarks, questions.

Rick Hawkins

to Chairman, a and American Horikawa, Peter is & ShouTi And Senior reason for Werther, Clayton, XX Ron comprised Vice previously for additional Thank brief currently our and clinical on prior research Rosenfeld. of Clinical advisory Janssen, Sciences there Dr. Bach there & release were we've for pleased we I'll is was Medical Research panel guidance open Medical R&D. on Board as Chief our Company, Scientific morning, and Dr. markets. with clinical joins Advisory at strengthen Ascendis Officer you, Since successfully clinical the Dr. will Vice and joining updated my pediatric CSAB. call positions President Head our Mark appointment spent over turning for research before XXXX. remarks Reiko clinical nine This management Johnson Operations provide the teams pharmaceutical building we keep his we is enter Dr. board at of our concluding Medical Pharma. to our his begin team. George CSAB Clinical leading extensive Prior taken endocrinologist Dr. Dr. everyone, Lisa. noted Worldwide. distinguished experience, in and on the to Then Bach to of of responsibility I Dr. global a Pediatric of He including launched years my call. years Bach or increasing XX products ending us July tenure week, innovative and call Bach held Endocrinologist updates of the and colleagues programs. to results have issued thank trials Merck of worldwide that with for Ascendis, And time call we'll pharmaceutical today's Asia development Head our clinical your detailing a you to held on press of Johnson, Bach financial good morning, a Pacific and China second Last our enhance at results. President subsidiary Janssen, and questions. steps Sciences experience to the our announce quarter

population. growth hormone experience and LUM-XXX a with brings and to growth scientific is on With in significant published conducted from of his as our formerly Dr. knowledge wealth the hormone offered Bach his of growth Now, understanding data early extensive medical hormone, disorders a journals. of advisory the unique known and LUM-XXX, IGF-X, career, MK-XXXX. and clinical related board He in deficient preclinical and research advantages work to

discovering regulatory our Endocrinology contributions experience of Pharma through as and recognition Pharma's acting pharmaceutical team him Medicine. of for promotion Phase as School public a this has new Lumos serve planning to our Officer and we research University endocrinologist, in Pharma advancing has is in and in activities. international Officer. for industry, XX and academic He and to Lumos clinical Biopharma of his Health to part is Lumos all the Lumos on John led John years at extensive responsible the as marketing Chief of tropical an is look NCATS, he of well position his of clinical FDA and developing interactions has a Director NIH in as currently and was positioned was X, executive GH both National addition for including through nearly endocrinology Tuesday, adjunct diseases, role. and and Roche Vice and pharmaceutical recently, agencies endocrinology growth years for him And therapeutics private biotechnology since Clinical rare David preclinical of we and Directors. of new to with Chief based TransCon lead and hormone also President, Ascendis Research obviously treatment for And served of from the toward the he launch since Chief President XXXX, and on announced and is management with week, or once Executive neglected Advancing has he facets compounds David Chief Operating diseases. We the previously and the and friend clinical contributions by hormone of LUM-XXX to strategy. multiple the years Operations during of respected XX And expansion Scientific experience he our of Most currently announced to John's clinical for of advanced our he Science to partnerships he management the He professor conducted contributions Medical therapeutics the my where where a of as previously Pharma an joining including therapeutic of experience approval. of clinical Translational of primarily development, earlier and And Scientific NCATS, Institute companies. collaborative clinical his biopharmaceutical by diseases join David at growth Karpf, positions Merck, of and in the the has Officer with treatment biopharmaceutical Lumos accomplished leadership forward the LUM-XXX familiarity and advancement advancing at where and National at promotion therapeutic commercial Intramural as Development part our John esteemed Lumos Medical at board of President thrilled look forward as candidate succession April advisory protein served novel he advancing Pharma. he the both Board McKew companies. held assistance an weekly has field to at LUM-XXX. commercial several experience for served our work tenure Vice rare in the company aTyr Pharma, colleague successfully XXXX. and in his joined team being for gained have for served several in guidance the preclinical John deficiency. we of vital Division development. labs long-acting of to are Pharma, Group, research also several Clinical President Officer development, rare and PTSD and David's Pharma, of in this Center his commercialized also XX Stanford of clinical in prior Dr. And therapies of candidates our

David. welcome, So

David Karpf

for you, kind the afternoon your add I wanted I how only team. everyone, to join excited And Thank Rick to good introduction. am Lumos

that Merck. advance this on potentially clinical on is the deficiency Rick, and team very my look and to area. working and a my execute advance rest experience plan time has familiar for to of asset therapeutic as LUM-XXX oral patients an with to experience breakthrough long-acting at forward with John our mentioned, growth Rick assets my Lumos Based clinical a hormone treating LUM-XXX strategy. As I I'm I GHD, hormone well-developed developing therapy from the with growth these in a believe

Rick Hawkins

to before treatment potential the of and our point. want call breakthrough the on theme and visa view David welcome be of over update an again, common for you, held programs. LUM-XXX highlight is to that just Thank a endocrinology and And I John the clinical in turning for by to the therapy of experts many PGHD. oral

needed On the Lumos expectations. and potential, that talent place full advance put believe expertise to and asset this realize in commercial of strength its the has we

So John. to over I'll with turn call that, the

John McKew

Thank with welcome, you, Rick, working all to David. looking forward We're you. and

July on XX. provided updated guidance we our earlier, call mentioned Rick our on clinical As programs on

and in restrictions anticipated outcome As data of - a initially OraGrowtHXXX the presence international adapt population. sites, of of at a and of site prompted was for patient the the The as half pace trial patterns for to communities We persistent now primary expect extension XXXX. COVID-XX. six-month by to to children due readout second reminder, ongoing normalize patterns referral certain return COVID-XX slower to initiation further is this typical disruption school referral the

at of on plan we compared prior the therapy. to in first continue Separately, primary six the initiation beginning the six more We remains the pace to for the protocol trial trials. this to robust trial increase of also OraGrowtHXXX effects trial study OraGrowtHXXX The long-term extension provide to open previously readout package long-term an three-year of the for this the protocol data trial. and of year. we previous we as this additional capture in to for OraGrowtHXXX FDA for the Again, was of months future planned will trial, extension see the therapy extension mirrors announced LUM-XXX of trial half OraGrowtHXXX long-term to months filings. months request trial for This of proposed the six sites OraGrowtHXXX the study. to are new patients the screening for the outcome months regulatory OraGrowtHXXX data who As previous a extension responded treatment for XX on believe extension clinical enrollment our response this first data

trial in the the to for However, trial of effects treatment of small to site that a a a critical path period children adults a the small subsequently in pulsatility of the illustrate the months months. initiation on of from exists open-label XXX our for pharmacokinetic and is this X announced replicate initiation Phase that trial the LUM-XXX of currently We pharmacodynamic extension proposed study six trial. and PGHD announced not subset QX. XX data Phase from in of single and X in trial. We the OraGrowtHXXX OraGrowtHXXX was LUM-XXX

I of clinical to extend therapy Furthermore, program. initiated To these this the review data will to to financial for of patients. our over new assessment six standalone time was and OraGrowtHXXX months joining protocol enrolling enhance pulsatility at who trial We currently a PD data changes trial months The basis that, Lori, therapy timeline. her provide The package therapy. is will on the data. also CFO will our to recap The both do continue the on velocity anticipate role not second readouts and and six capture overall at is will height assessed supporting XX planned. for the quarter extensions Lori? June decided LUM-XXX we first a was in to in our extend OraGrowtHXXX to additional PK/PD turn trials With be development as as months originally results. call us for on

Lori Lawley

quarter afternoon, on with XXXX. through of to good operations totaling everyone. on OraGrowtHXXX six-month XX support million, XX, compared of OraGrowtHXXX trials. XXXX hand ended $XXX.X the to We expected and the QX, Cash as both $XX.X and second equivalents cash December the the data John June end from is cash and readout million Thanks, XXXX, on

in have the period in expenses expenses. of the million and million to clinical $X.X $X.X an primarily increase research The offset of quarter operational increase by We trial due a million, over change second an decrease XXXX. in expenses, $X.X is million of development and contract of and personnel for $X.X same manufacturing

the in million million. compared loss the net operational XXXX. million, an in $X.X spend This increase increase million of the Our for to period second The administrative it shares in $X.X point XXXX And will legal $X.X closing X,XXX,XXX quarter loss the in severance ended net in $X.X pro XXXX. an outstanding. were is expenses recording primarily $X.X expenses million, QX, was compared to to with of personnel-related of offset million expenses for back remarks. period a consulting with decreases of by to general I forma quarter to that for due the increase same We of Rick same CFO turn and due second $X.X and

Rick Hawkins

Lori. you, Thank

key clinical Advisory say your Board leaders we've So just I our our to discussions LUM-XXX with to want in opinion expand advanced our platform. before questions, taking Scientific

LUM-XXX of Stature, We Syndrome, for for Syndrome, subset Gestational Age. are a in other for We're Turner pipeline Small we're certain including and and and and actively clinical reviewing forward indications phase the and pathway affected Idiopathic our potential Children discuss a Prader-Willi patients and look Short confident belief ready when represents to LUM-XXX advancing to next lifecycle of updates comprehensive further the provide a that LUM-XXX product the plans. we’ll Born

our and leadership Lumos decisions consideration In are and significant ability select we're and each provides management new to product trends add development and long-term referrals evaluate the John, and our pediatrician judicious and OraGrowtHXXX best and portfolio. roles to I in to for being accelerated see resume, and addition, what for And for Mark reopen our highly disease company. recent we enrollment on their visits on our should company selective as this expertise trials that OraGrowtHXXX both and increased clinical Pharma’s will of developments to process, fall. as enrollment stated trials and shareholders. creation and positive David strengthen in value with screening to and encouraging focus our strategy. continue execute assets our under clinical enhancement rare the We before, schools our corporate believe we The bring team on

take we're questions. So now with that to operator, ready

Operator

Piper line Sandler. [Operator Instructions] of of Rahimi comes question from the Your Yasmeen first

open. Your line is

Unidentified Analyst

Felicia This for you our Yas, on so for taking questions. much thank is

could first, your So additional do that be please provide just morning guys pipeline while that? expansion line build if and is no, finish we we this of current getting your you to enrollment two opening LUM-XXX you little have you'll to studies? timelines? And for maintain XXXX free in expecting we pipeline, also wondering yes And of XXXX? next to think a OraGrowtHXXX And color should sites sufficient OraGrowtHXXX balance if Thank you. were cash or bit on the or up be

Rick Hawkins

believe the The time, for a I concern COVID-XX. first question, anticipated some we've over quite

mentioned are So I’ve the a XX time I also we're ago. sites. And broad we expansion think as site earlier, some sites sites And in of to And open rest about quite do there's geographic very rapidly open. majority those trying to advancing the of distribution.

that's to sites, we too, I beyond XX about right again, planned XX So think us once or going to now. have help but

want that that to And to our or want at judicious into I readout robust we going our same to judicious in cash, going strong in the of think may It more asset. at to to that's careful we're the our place. to be in a anything of This preclinical anything that can looking that to position. And XXX in we the also close want studies. sufficient XXX have emphasize meet enrollment. have very were much Lori said, being And company. we in bring be our very get us are bring and terms as the up we're review open time, we a But means in as review clinic. to of an process to we to in assets a more actually that on

Operator

Thank you.

Duncan Your the next line Cantor Fitzgerald. of of comes Charles from question

open. Your line is

Charles Duncan

well as if as morning. had the management you Thanks, Congrats questions. taking for Rick on of I and update the a the Yes, team. new all couple joiners, call. good on team my will,

you're help I'm the study, could screen perhaps the you the looking rates First and versus second PEM. that screen the us ‘XX maybe in of remind just the understand me enrollment like just XXX failure half of for given terms seems like It if data. of half long. and a for LUM I guess John, wondering And all, is or year study seems a to this rates of it enroll

it being perhaps is So conservative? you're that overly

Rick Hawkins

John, ahead. go

John McKew

failure let's rate. So the screen about can - talk first we

failure a rate screen of PEM think who diagnosis are the patients the I part assessment of is important our which here. percentage So the positive, PGHD or with

analysis As very on we able XX we there least as in is Phase the offs to a a much dataset then do of called we've to were with broader the assessment for dataset on which smaller large dataset, that X study, PEM common in be GeNeSIS human growth study. nice our hormone the yearlong we're based our Journal cut that Obviously, much an of a working generate positive. large the published did a And screens were and dataset, a very patients scale, about XX% product. Science would of we Endocrine recently, apply multinational that’s experienced PEM

have expect be the So going as dataset. telling that we to don't to that - GeNeSIS is data as

failure I for I screen we the COVID-XX. of based conservative, think primarily and to it And to that, about not achieve that of would that guide pace than to based a on think hard is think say recruitment what So set. achievable. a slow other really process but we are primarily only the And can anything failures, that's second that patient were the about well re-guiding, beat want that. we timeline is being screen we on that attributed primarily, delays work very that's the isn't really do it will isn't to slow then I part just we a market recruitment,

Charles Duncan

Okay. ahead. Go Go ahead.

John McKew

question. Chase. prediction be status. might believe certainly patients, its add that, there's everybody's number it's screen There's new mean concern our our the with We in a of And stage. conservative about mind want COVID-XX. So current to But no this in I I the at encouraging.

Charles Duncan

release but you with intrigued interested what a to question in, and of join Dr. upfront, hormone, mechanisms? may, And than, different that replacement Karpf, then why if convenience put benefit, how of I'm simple And if And different I'm dismissive you your therapy. particularly that and compliance and thoughts but I'm wondering and those of may the spot. a And being basically I'm a Secretagog apologize LUMO. pulsatile on just really, growth on be mechanistically of I'm say, the could not I is, Okay. I provide kind going

John McKew

more Well, with could you agree not I actually.

of I at modalities, with mean, XXX mostly one growth been been very design that, can multiple daily, I with, hormone a a is take the a time a enhanced basal normal to among weekly, about about was was when And mean, what I is talk at at growth Merck replacements. It's hormone physiological spurts marvelous did neither I knew molecule for mean it peaks. once growth known have of long night which what the access, was those basically take precisely morning, in I the struck I an low So a agent, I once attracted and normal oral that actually with the recapitulates, evening, talk was the of peaks. simply it you drug. is

was when interested of company all Now, I a the large was populations, was rare at that in antithesis they indication. orphan about Merck, a Merck were

and So drug, wanted lacked this a a I out try big to in which they unfortunately the designed continues and search to endpoint. they chose a elderly, to registration think beautifully was lack sarcopenia and population,

excited osteoporosis of development large Michael attempt, to this market make I about They molecule. colleague was I'm PGHD. think license did Horner very a that of for faith it So a mine, this. in had this. in their enough out hypertension, But they And like to hyperlipidemia,

excites when XXX what I on bullish in. last retired I September, sales. far bullish, three TransCon called physician. patients, and But have effective. I'm happy some about very really MBAs been I that Well, to growth into mean three effective realized soon, hormone. time for really I've really about not opportunity my any back brought and I'm last what and drug need bring drugs less bullish in this need. at a a great pass it little Sanders mean, Now to so full chance a third was bringing I My potential that this unmet getting very what and doing I'll Rick two unmet effective bit I of to a see I've with a medical significant consulting. molecule of When from was. And me able patients. I really patients I so intention but LUMO seeing to at I me time Stanford patients did drug is And view

this growth good very, that very be their answer hormone deficiency. question? Did think I patients, will treatment your the appropriate for I a of

Charles Duncan

regard have of of a wondering, aspect want forward terms with Last really Yes, to absolutely. you well. pipeline, guess, and move pipeline appreciate competed Rick, it that And latter or I looking relative forward perhaps mentioned in in all to to is that leading would it the I'm wondering that on the color. question other you me favorite, that to additional to candidate. would if strategy? capital as would promising against have of indication guess of with you with it for I'm of seeing product, LUM-XXX? kind in-licensing And look to it a and LUM me - hands route seem seem the strategy. I I'm and terms opportunities, And for it's one, your there's the kind you're at you being a to full how indications markets highlight a a you that

John McKew

I It’s say good focused remains priority Chase. executing first to our XXX OraGrowtHXXX on to study and want that, And stay on study foremost, plan. question and our

there as unique and engaging be cooked. to fully first this beneficial indication important time know. plans, And opportunity provide. KOLs of that those plans our be lay other did this obviously think more and I would we to out when going because unique the evaluating because the with compound, provide action of our at a updates we mechanism - likely compound and I we're you'll - appropriate of also the we're all on are out are this of But

assets on continue opportunities it's our out prudent I us, backgrounds to though space, continue, to look think based rare in to other disease they’re for there. extensive for the

a anything. this we as doing and do, trigger we know, and quite been we because as on for to careful you haven't possibly sure been a unique that that's And strong for judicious asset, pulled imprudent the our like process we unique make that place shareholders it’s assets some that's it. to Because it to But Now have want value can. in all us as and the we've to just not anything we're time, think if developing is would I a in be we for that proposition find LUM-XXX. have

Charles Duncan

Very good, update. appreciate for taking thanks And my the question.

Rick Hawkins

Thanks.

Operator

Your line next of White Ed of comes the Wainwright. H.C. question from

Your line is open.

Ed White

Good morning, thanks for taking my questions.

So maybe give start are we as R&D trend you expense? R&D with for can going on sequentially expect were be the see wondering the thinking us up a how the I'm curious quarters R&D question for some spend to next about going should thoughts just Lori as would initiated if We to two forward? trials down. expenses

Lori Lawley

and question. Sure, the you for thank

we our we spend and had And our expect the anticipate QX what reflective so, - trials would is some former forward approximately Phase register and advance million. expect recorded CMO increases $X.X costs I severance of trial. towards as QX, sequentially compared X departure QX of going that that we of clinical to will with in were forward for towards path the our

Ed White

to title. that? within give thoughts any if Great, thank the - just changing can I’m new role your congratulations And your role how wondering on us you. John is and company you

John McKew

been Well, thank I playing. congratulations similar continue focus for I really, and you have will to think role the to Ed the the be

operational where sure of the aspects to both all that making aspects be scientific able and the company it's focus a our we promotion on and of think I deliver guidance. I'll the on

Ed White

about curious last Okay. things. the the And enrollment study. maybe I just have, on two we've in I'm been XXX question just talking And

be when telling go we're when then these we to the the give you studies in as plan pediatrician Delta us into how us on We just had process what is that And studies. And enrollment halfway the variant? you there you're about perhaps over more - back what how actual Thank see enrollment that do more that will enrollment you thought maybe on two I'm there few an trends. us could could mentioned next your Now updates be update you in going? on visits. going is the or get, children seeing, could school, you. the quarters, are thinking on interest wondering giving see perhaps you

Rick Hawkins

Yes, with I'll start that Ed.

haven't we're or quarters or we sure to any when in the that grindstone too the just to time - - through. We noses that a quarter three we're just more stated little guidance We're as have we're away on. study going would at doing it as goes make a it's well our but address to the trying address everything sure possible. to we appropriate we now, right at can make time, market the early do Perhaps bit half

Lisa Miller

question Delta And impact. John, virus could regarding you take his first the

John McKew

is variant like Yes, so Delta the was think alpha I the much variant last right. year,

home, mentioned, area-to-area people our those New sites the sites sites of from of also an things we past the sites interacting the getting about much internationally to we have are Rick geographies at in pandemic sites regardless has various in waxes have clinical in was learning more And delays Australia, remote us as also through how imagine two entire to are of this who as and at going for I where Eastern Zealand. and to way Part and Europe communities And kind running. to our in through I of up the But hard from - U.S., the through go juggle, than the another So right lawyers and help time. mentioned, as we I the with getting plan really would of around think point move spread and XX% live have with now we school COVID-XX. running. in have that up learn we is, we amount of enormous those across which wanes. and contract IRB's but year think starting seemed it's working think that that I year. with up And past, don't, are delay combination,

pediatrician the will be find we pediatric will endocrinology. think referrals kids, to which to educating trips and successful I in stimulate ways to the in

Rick Hawkins

John enrolled really experience the sites delay BtH I the getting is impact. diagnosed, kid I If it initiated. kid even under parents the treated. he transplant exactly mean getting just just endorse epidemic said, Because But want this is once mirrors my could COVID, said, the studies a which initial is absolutely meaningful a what have not what did

impact site. really was subject a there the So in into minimal coming

All of site site you initiated. in to to the all a through getting the really initiated the delay go got and was get hoops

with trial John LUM-XXX what So said I endorse want just as to to that. well. that the about happen I expect

Ed White

question. Great, thanks for taking my

Rick Hawkins

Thank you, Ed.

Operator

comes next of line the from Your [Kim Yung] question of Jeffries.

line is open. Your

Unidentified Analyst

in Thanks good calling Hi, [indiscernible] taking question. This for I morning. question. one have quick Kim is my UG

you Phase that the the to activity positive you'd royalty before compare the starting where study ask population? have Thank LUM-XXX of do versus LUM-XXX in the and that for PEM X positive might show So to negative advantageous additional PEM you. think efficacy has agencies selective

Rick Hawkins

I'll just start tell perhaps question that think you David with arrived, has finished let Dr. I it. Karpf and since let John that

David Karpf

a but ahead. making go comfortable I'm at Yes, that, stab

John McKew

published dramatic have up works that think, set there PEM here positive on previous and separated and and data And we've obviously, I analyzed, difference. we've so Yes that. is we we've negative,

And show this the data, actually, prospectively remember, them physiology, right. I appreciate be work So think that positive will into well, effectively. the enrichment is really market based I to patients, bringing and really the ongoing selecting strategy to this and is on that enrichment as that do our think, going PEM does strategy the trial, those proof FDA,

endogenous to enough not basically active don't to PEM drug, access. kids somatotrophs, stimulate They going the growth the of they're have our release they So growth were which an can't be is respond just have hormone. don't able to to hormone store going negative,

So offsetting. data, think I it And to regulators, look in we cut growing, setting how can it to tied case enrich that but a can well population is positive as mathematical that PEM the our when that physiology. as kids at to generated we show scientific seems you that very we make with we're as responders long to of show able effectively as are

evidence. will sufficient think I be that

Rick Hawkins

want do David, to And you anything? add

David Karpf

on can day American other the following. with my upon authority years is the metabolic I I'll hand, that, the the think Yes, say my But based with at just XX the say hand, I group, dealing experience one some on of company. this second

thrilled First of agents are pretty they're the like would best agencies all, drug. be for the selection process identify absolutely I payers think at the the to

if that XX-month That between be would for close guesstimate, zero versus lot for for the no be growth be I study. I or a PEM unselected to PEM be about of be daily having two daily willing the the to be PEM negligible. money. have versus Phase randomization a to a go have X Phase negative, basically to cap likelihood patients positive one study it'd hormone. And patients I and of versus think unselected we're a trial, as selected LUM-XXX Group I hormone. the for that. will There's any growth would rationale as to selected, It'll bet PEM X

see. shall You

Unidentified Analyst

Great, thank you.

Operator

comes line of from Catherine Jones at last question Novack Your the Trading.

line is Your open.

Catherine Novack

on couple Hi, questions. thanks expansion possibilities. had much pipeline for my I very taking a

specifications terms some are of what opportunities, that makes BD potential in your assets you about think that you in looking at sense portfolio? as you're think First,

Rick Hawkins

always starting thanks know, criteria proposition And a and included really your our good rationale, strong a a shareholders. really you with is fit, for Catherine, strategic value question. scientific our strong for

we look criteria. judicious opportunities it the you David to But, on and going In trigger at. But are look very space. to think our so in a at to our early really hasn't met endocrine I of to to I have going us think very with good stage anything have arriving, all, lot like selective the a willing process, one. I know, we'd continue We haven't the opportunities, the do because stay we and mean, careful especially in to will on a as experience, and pulled for you're basis. been expand above is

Catherine Novack

that Thanks, where then, is when of patients the about you're mechanism what makes unique Do approved. hormone an sense. benefit other indications you have expanding into idea And subset LUM-XXX might of these of from XXX LUM action? growth thinking

Rick Hawkins

that. with don't why you start John,

John McKew

growth population been in that LUM-XXX hormone PGHD population, now only tested. the deficiency is it's the So Right right.

of growth the back their to a the PEM we rate, have that's So population, correlation outcome. tests,

to, etiology the like of the unique in revenue of facets no disease, each So and other has indications right. to is approved growth the

activity. growth there some deficiency, are hormone there or things, one downstream are and some there IGF receptor Sometimes of activity modulation is

where that and overall those affect thinking looking, also really we've really each time of versus is the pulsatility trying of been LUM-XXX that's through understand all So the to potential in would those area, spending our looking facets states through and disease how right. individual bolus,

once for So release our stimulating indications. frank the of action And other we're of hormone is that, right each about And an data PGHD. where going have in our of really, going the might together we how indications, then, endogenous mining, go try in we really to indications. that's And growth impact history understand can put get one one play we that's these these the one assess some we that building deficiency after have of these hormone through of to past growth dataset mining, good and how prioritized that indicator diseases itself, mechanism want we're do each list is where forward. of now, ideas of to that of an what each to of of of information to be

Catherine Novack

much. Thank you very

Rick Hawkins

Thank you, Catherine.

Operator

Thank I'll you Hawkins call closing this Mr. questions for back queue. no remarks. time, the am At I to the in showing hand further

Rick Hawkins

us we you course thank of Thank for and program keeping the we of you apprised Well, our forward the look joining to year. everyone much. over today very

Operator

concludes Ladies for Thank you today's conference gentlemen, call. and this participating.

disconnect. now may You

Lumos Pharma (LUMO) 5 Aug 212021 Q2 Earnings call transcript